Skip to content

IDEAYA Biosciences

US · IDYA #2357 by market cap Listed 2019
25.56 -0.61 -2.33%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

✦ Quant Ownership Signal how this is computed

Distributing
  • The number of reporting institutions increased by 1 in the most recent period (2026/Q3).
  • Total institutional ownership fell 0.7 percentage points.

Ownership vs. money flow

Aligned

Institutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
107.09% -0.74pp
Institutions
351 +1
As of
2026/Q3 vs. prior period

Holder types

Mutual Fund78.72%
Hedge Fund19.60%
Public Company4.20%
VC/PE Fund2.41%
Government Pension Fund0.88%
Individual/Insider0.88%
Insurance Company0.55%
Private Company0.39%
Endowment Fund0.23%

Top holders as of 2026-09-30

FMR 14.96% · 14.47M sh
BlackRock 9.87% · 9.55M sh
Janus Henderson Group plc 8.87% · 8.58M sh
Capital Research 5.52% · 5.34M sh
Baker Bros. Advisors LP 5.18% · 5.01M sh
Vanguard Capital Management, LLC 4.46% · 4.31M sh
State Street Global Advisors 4.06% · 3.93M sh
Logos Global Management, L.P. 3.10% · 3.00M sh
Adage Capital Management, L.P. 2.81% · 2.72M sh
Deerfield Management Company, L.P. 2.81% · 2.71M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 42 buys · 6 sells

NameRoleStake
Yujiro Hata Chairperson & CEO 0.71%
Jason Throne Former Chief Legal Officer & Company Secretary 0.07%
Jeffrey Stein Independent Director 0.06%
Andres Briseno Chief Accounting Officer 0.03%
Terry Rosen Lead Independent Director 0.01%
Douglas Snyder Chief Legal Officer 0.00%
Wendy Yarno Independent Director --
Scott William Morrison Independent Director --
Catherine Mackey Independent Director --
Darrin Beaupre Chief Medical Officer --

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-10-05 Yujiro Hata Chairperson & CEO Derivative Exercise and Sale -26,338 $4.31–38.26
2026-07-06 Andres Briseno Chief Accounting Officer Derivative Exercise and Sale -9,550 $12.86–40.01
2026-06-15 Wendy Yarno Independent Director Other Derivative Acquisition +20,000 $30.57
2026-06-15 Jeffrey Stein Independent Director Other Derivative Acquisition +20,000 $30.57
2026-06-15 Scott William Morrison Independent Director Other Derivative Acquisition +20,000 $30.57
2026-06-15 Catherine Mackey Independent Director Other Derivative Acquisition +20,000 $30.57
2026-06-15 Terry Rosen Lead Independent Director Other Derivative Acquisition +20,000 $30.57
2026-06-15 Malcolm Hampton Independent Director Other Derivative Acquisition +20,000 $30.57
2026-03-01 Jeffrey Stein Independent Director Open Market Acquisition +50,000 $32.96
2026-01-29 Yujiro Hata Chairperson & CEO Other Derivative Acquisition +600,000 $32.19
2026-01-29 Douglas Snyder Chief Legal Officer Other Derivative Acquisition +130,000 $32.19
2026-01-29 Darrin Beaupre Chief Medical Officer Other Derivative Acquisition +175,000 $32.19
2026-01-29 Andres Briseno Chief Accounting Officer Other Derivative Acquisition +80,000 $32.19
2026-01-29 Michael White President of Research & Development Other Derivative Acquisition +190,000 $32.19
2026-01-29 Stuart Dorman Chief Commercial Officer Other Derivative Acquisition +155,000 $32.19
2026-01-29 Joshua Bleharski Chief Financial Officer Other Derivative Acquisition +170,000 $32.19
2025-11-27 Douglas Snyder Chief Legal Officer Other Acquisition +2,080 $16.91
2025-11-27 Andres Briseno Chief Accounting Officer Other Acquisition +1,935 $16.91–23.26
2025-06-26 Joshua Bleharski Chief Financial Officer Initial Statement of Beneficial 0 --
2025-06-23 Wendy Yarno Independent Director Other Derivative Acquisition +20,000 $21.78

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

IDEAYA Biosciences discussion 0 comments

Add a comment